11 recruiting, 10 completed, 7 active not recruiting, 5 not yet recruiting. 22 Phase 2, 18 Phase 1, 6 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Head and Neck Squamous Cell Carcinoma (HNSCC): new trials by email Literature Review of Head and Neck Squamous Cell Carcinoma (HNSCC) trials Research Report on Head and Neck Squamous Cell Carcinoma (HNSCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Not yet recruiting | University Health Network, Toronto | 48 | 2026-11-01 | 2026-10-22 |
| [18F]-AraG PET Imaging in LA HNSCC [18F]-AraG radiotracer, Chemotherapy, Radiotherapy - Head and Neck Squamous Cell Carcinoma (HNSCC), Locally Advanced Head and Neck Squamous Cell Carcinoma | Early Phase 1 | Not yet recruiting | Indiana University | 5 | 2026-09-01 | 2026-07-22 |
| Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel - Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 182 | 2026-04-20 | 2026-07-09 |
| A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma FDC fianlimab+cemiplimab, Cemiplimab, Placebo - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 120 | 2026-04-14 | 2026-10-22 |
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors EXS74539 - Solid Tumor, Small Cell Lung Cancer (SCLC) | Phase 1 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 40 | 2026-04-13 | 2026-06-10 |
| Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC Ficerafusp alfa, Pembrolizumab - Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2026-03-26 | 2026-03-27 |
| A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D) - Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma | Phase 1 / Phase 2 | Recruiting | Cellid Co., Ltd. | 37 | 2026-02-04 | 2026-07-08 |
| Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma Tislelizumab - Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC | Phase 2 | Active not recruiting | Sun Yat-sen University | 24 | 2025-06-25 | 2026-08-07 |
| AK129 Combination Therapy for Advanced Solid Tumors AK129(dose 1), Pemetrexed, Paclitaxel - Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 / Phase 2 | Recruiting | Akeso | 230 | 2025-05-21 | 2025-06-03 |
| Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET [18F]-olaparib PET scan - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 / Phase 2 | Not yet recruiting | University Medical Center Groningen | 10 | 2025-05-01 | 2025-04-18 |
| A Study of MT-4561 in Patients With Various Advanced Solid Tumors MT-4561 - Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | Tanabe Pharma America, Inc. | 27 | 2025-04-18 | 2025-12-11 |
| Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. Cetuximab/avelumab - Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 67 | 2025-02-20 | 2025-03-14 |
| Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Trilaciclib - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Not yet recruiting | Shandong Cancer Hospital and Institute | 30 | 2024-12-15 | 2024-12-03 |
| Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma Head and Neck Cancers - Head and Neck Squamous Cell Carcinoma (HNSCC) | Not applicable | Active not recruiting | Sun Yat-sen University | 50 | 2024-09-26 | 2026-09-30 |
| A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma MRG003 combined with Pucotenlimab, MRG003 combined with Pucotenlimab+Cisplatin - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Not yet recruiting | Lei Liu | 30 | 2024-08-01 | 2024-07-31 |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC INBRX-106, Pembrolizumab - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 / Phase 3 | Active not recruiting | Inhibrx Biosciences, Inc | 410 | 2024-05-14 | 2026-05-08 |
| Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma Netopitam Palonosetron capsules and dexamethasone - Head and Neck Squamous Cell Carcinoma (HNSCC) | Not applicable | Unknown | Sichuan Cancer Hospital and Research Institute | 36 | 2023-11-01 | 2023-10-26 |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers AB598, Zimberelimab, Fluorouracil - Advanced Cancer, Advanced Malignancies | Phase 1 | Active not recruiting | Arcus Biosciences, Inc. | 40 | 2023-10-13 | 2026-09-29 |
| A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies AP203 - Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | AP Biosciences Inc. | 168 | 2023-07-24 | 2025-03-26 |
| Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors GTAEXS617, SoC - Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 230 | 2023-07-06 | 2026-08-13 |
Showing 20 of 40. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (40) · Carcinoma, Non-Small-Cell Lung (10) · Head and Neck Neoplasms (7) · Ovarian Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Prostatic Neoplasms (3) · Stomach Neoplasms (3) · Uterine Cervical Neoplasms (3) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Squamous Cell (2) · Carcinoma, Transitional Cell (2)
Neoplasms (40) · Neoplasms by Histologic Type (40) · Neoplasms by Site (40) · Neoplasms, Glandular and Epithelial (40) · Carcinoma (38) · Carcinoma, Squamous Cell (38) · Head and Neck Neoplasms (33) · Respiratory Tract Diseases (11) · Respiratory Tract Neoplasms (11) · Bronchial Neoplasms (10) · Carcinoma, Bronchogenic (10) · Lung Diseases (10) · Lung Neoplasms (10) · Thoracic Neoplasms (10) · Digestive System Diseases (8)
pembrolizumab (7) · Nivolumab (6) · Carboplatin (5) · Cetuximab (4) · Cisplatin (4) · Drug Therapy (4) · Radiotherapy (4) · Docetaxel (3) · Fluorouracil (3) · tislelizumab (3) · Ipilimumab (2) · Paclitaxel (2) · Pemetrexed (2) · Radiosurgery (2) · relatlimab (2)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (2) · Icahn School of Medicine at Mount Sinai (2) · RTOG Foundation, Inc. (2) · Sun Yat-sen University (2) · AP Biosciences Inc. (1) · Akeso (1) · Arcus Biosciences, Inc. (1) · Bayer (1) · BeiGene (1) · Boehringer Ingelheim (1) · Cellid Co., Ltd. (1) · Centre Antoine Lacassagne (1) · Centre Leon Berard (1) · Dan Zandberg (1) · Dana-Farber Cancer Institute (1)
United States (25) · France (8) · Australia (7) · China (6) · South Korea (6) · Spain (6) · United Kingdom (6) · Canada (5) · Italy (5) · Taiwan (5) · Poland (4) · Belgium (3) · Israel (3) · Malaysia (3) · Austria (2)
Bonnie C Abbruzzese, MS RD (1) · Dan P Zandberg, MD (1) · Dan Zandberg, MD (1) · Glenn Hanna (1) · Hye Ryun Kim (1) · Julia Kazakin, MD (1) · Liu-Wei Tang (1) · Marshall Posner, MD (1) · Maura Gillison, MD, PhD (1) · Michel van Kruchten, MD, PhD (1)
PMID 24051744, PMID 25670018, PMID 32822275, PMID 33605440, PMID 35296845, PMID 35688554, PMID 36228746, PMID 36383907, PMID 36457575, PMID 40347227, PMID 40499147
2023 (2), 2018 (1), 2019 (1)